Term ends Jan 1, 2028 · High confidence
20-year base term ended Nov 3, 2026
Held by Orvida Pharma Ltd.
Filed Nov 3, 2006 as application 11/592,783 · Granted Feb 22, 2011
Base term plus 424 days of patent term adjustment (USPTO delay)
Today
2006
2028
Clock starts
Nov 3, 2006
Nov 3, 2006
Term ends
Jan 1, 2028
Jan 1, 2028
Granted
Feb 22, 2011
Feb 22, 2011
base term
patent term adjustment
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
424
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
8
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 424 days past its 20-year base term on prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 3, 2006, when this application, 11/592,783, was filed | Nov 3, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +424 days, USPTO patent term adjustment record | Jan 1, 2028 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jan 1, 2028 | High confidence |
This family
| US 7,803,790 | Lapsed on the fee record Sep 2022 | Sep 2022 |
| US 7,893,260 | this patent Jan 2028 | Jan 2028 |
| US 8,916,550 | Lapsed on the fee record Dec 2022 | Dec 2022 |
| Application PCT/US2007/024100 | PCT application no patent term | no patent term |
| Application 12/755,118 | Abandoned not computed | not computed |
| US 8,552,009 | Term ended Nov 2026 | Nov 2026 |
| Application 14/014,636 | Abandoned not computed | not computed |
| Application 15/052,385 | Abandoned not computed | not computed |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Mar 27, 2007 Reel 19073, frame 647 | Chong, Jayhong A.; Fanger, Christopher; Larsen, Glenn R.; Lumma, JR., William C.; Moran, Magdalene M.; Ripka, Amy; Underwood, Dennis John; Weigele, Manfred; Zhen, Xiaoguang | Hydra Biosciences, Inc. | Assignment of Assignor's Interest |
| Jan 6, 2009 Reel 22072, frame 174 | Mahadevan, Anu; Meltzer, Peter | Organix, Inc. | Assignment of Assignor's Interest |
| Jan 6, 2009 Reel 22072, frame 177 | Organix, Inc. | Hydra Biosciences, Inc. | Assignment of Assignor's Interest |
| Mar 21, 2019 Reel 48660, frame 606 | Hydra Biosciences, Inc. | Kamari Pharma Ltd. | Assignment of Assignor's Interest |
| Apr 28, 2026 Reel 75491, frame 196 | Kamari Pharma Ltd. | Orvida Pharma Ltd. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Jan 2028
Term ends Jan 1, 2028. No further fees fall due before then
Note
The 424 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
37
later US patents cite this one
That is top 25% of utility patents granted in 2011 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.